MNTA’s 4Q10 revenue from the Lovenox profit share was $52.4M, 31% of the $170M of 4Q10 in-market Lovenox sales booked by NVS. For profit-share calculation, NVS’ Lovenox operating margin in 4Q10 was 68.5%.